The pathogenesis, diagnosis and treatment of Raynaud phenomenon

Nature Reviews Rheumatology

Volumn 8, Issue 8, 2012, Pages 469-479

  Herrick, Ariane L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANALGESIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIOXIDANT; BOSENTAN; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; FASUDIL; ILOPROST; IMMUNOSUPPRESSIVE AGENT; NEUROTRANSMITTER; NITRATE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE INHIBITOR; PROSTANOID; QUINAPRIL; SEROTONIN UPTAKE INHIBITOR; STEROID; UNIPROST;

CAPILLAROSCOPY; CLINICAL EVALUATION; DRUG INDUCED HEADACHE; FINGER ULCER; FLUSHING; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIA; MEDICAL HISTORY; MICROVASCULATURE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SIDE EFFECT; STEROID THERAPY; STRATEGIC PLANNING; SYMPATHECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THERMOGRAPHY; THROMBOCYTE ACTIVATION; TREATMENT PLANNING; VASCULITIS; VASOCONSTRICTION; VASODILATATION;

BLOOD VESSELS; CAPILLARIES; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; MALE; NAILS; RAYNAUD DISEASE; SEX FACTORS;

EID: 84864625242     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.96     Document Type: Review

References (123)

1. Maricq, H. R. et al. Geographic variation in the prevalence of Raynaud's phenomenon: A 5 region comparison. J. Rheumatol. 24, 879-889 (1997
2. Silman, A., Holligan, S., Brennan, P. and Maddison, P. Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ 301, 590-592 (1990
3. Suter, L. G., Murabito, J.M, Felson, D. T. and Fraenkel, L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum. 52, 1259-1263 (2005
4. Carpentier, P. H., Satger, B., Poensin, D. and Maricq, H. R. Incidence and natural history of Raynaud phenomenon: A long-term follow-up (14 years) of a random sample from the general population. J. Vasc. Surg. 44, 1023-1028 (2006
5. Walker, U. A. et al. Geographical variation of disease manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann. Rheum. Dis. 68, 856-862 (2009
6. Hartmann, P., Mohokum, M. and Schlattmann, P. The association of Raynaud's syndrome with rheumatoid arthritis-a meta-analysis. Clin. Rheumatol. 30, 1013-1019 (2011
7. Raynaud, M. Local Asphyxia and Symmetrical Gangrene of the extremities 1862, and New researches on the Nature and Treatment of Local Asphyxia of the Extremities, 1874. (New Syndenham Society, London, 1888
8. Lewis, T. Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart 15, 7-11 (1929
9. Charkoudian, N. Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans. J. Appl. Physiol. 109, 1221-1228 (2010
10. Johnson, J. M. and Kellogg, D. L. Local thermal control of the human cutaneous circulation. J. Appl. Physiol.109, 1229-1238 (2010
11. Herrick, A. L. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 44, 587-596 (2005
12. Gunawardena, H., Harris, N. D., Carmichael, C. and McHugh, N. J. Maximum blood flow and microvascular regulatory responses in systemic sclerosis. Rheumatology (Oxford) 46, 1079-1082 (2007
13. Rossi, M. et al. Blunted increase of digital skin vasomotion following acetylcholine and sodium nitroprusside iontophoresis in systemic sclerosis patients. Rheumatology (Oxford) 47, 1012-1017 (2008
14. Wigley, F. M. Vascular disease in scleroderma. Clin. Rev. Allergy Immunol. 36, 150-175 (2009
15. Cotton, S. A., Herrick, A. L., Jayson, M. I. and Freemont, A. J. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J. Pathol. 189, 273-278 (1999
16. Ibba-Manneschi, L. et al. Variations of neuronal nitric oxide synthase in systemic sclerosis skin. Arthritis Rheum. 54, 202-213 (2006
17. Blaise, S. et al. Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. J. Rheumatol. 36, 984-988 (2009
18. Anderson, M. E. et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford) 41, 324-328 (2002
19. Vancheeswaran, R., Azam, A. Black, C. and Dashwood, M. R. Localization of endothelin 1 and its binding sites in scleroderma skin. J. Rheumatol. 21, 1268-1276 (1994
20. Pignone, A. et al. Reduced circulating levels of angiotensin (1-7) in systemic sclerosis: A new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann. Rheum. Dis. 66, 1305-1310 (2007
21. Zamora, M. R. O'Brien R. F., Rutherford, R. B. and Weil, J. V. Serum endothelin 1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 336, 1144-1147 (1990
22. Campbell, P. M. and LeRoy, E. C. Pathogenesis of systemic sclerosis: A vascular hypothesis. Semin. Arthritis Rheum. 4, 351-368 (1975
23. Rodnan, G. P., Myerowitz, R. L. and Justh, G. O. Morphological changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine (Baltimore) 59, 393-408 (1980
24. Hasegawa, M., Nagai, Y., Tamura, A. and Ishikawa, O. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br. J. Dermatol. 155, 1159-1164 (2006
25. Ho, M., Veale, D., Eastmond, C., Nuki, G. and Belch, J. Macrovascular disease and systemic sclerosis. Ann. Rheum. Dis. 59, 39-43 (2000
26. Fleming, J. N. and Schwartz, S. M. The pathology of scleroderma vascular disease. Rheum. Dis. Clin. North Am. 34, 41-55 (2008
27. Kahaleh, B. Vascular disease in scleroderma: Mechanisms of vascular injury. Rheum. Dis. Clin. North Am. 34, 57-71 (2008
28. Trojanowska, M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat. Rev. Rheumatol. 6, 452-460 (2010
29. Laplante, P. et al. Novel fibrogenic pathways are activated in response to endothelial apoptosis: Implications in the pathophysiology of systemic sclerosis. J. Immunol. 174, 5740-5749 (2005
30. Rajkumar, V. S. et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res. Ther. 7, R1113-R1123 (2005
31. Kuwana, M., Okazaki, Y., Yasuoka, H., Kawakami, Y. and Ikeda, Y. Defective vasculogenesis in systemic sclerosis. Lancet 364, 603-610 (2004
32. Manetti, M. et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ. Res. 109, e14-e26 (2011
33. Bukhari, M., Herrick, A. L., Moore, T., Manning, J. and Jayson, M. I. Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis. Br. J. Rheumatol. 35, 1127-1131 (1996
34. Hirschl, M. et al. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: Results of ten years of prospective surveillance. Arthritis Rheum. 54, 1974-1981 (2006
35. Chikura, B., Moore, T., Manning, J., Vail, A. and Herrick, A. L. Sparing of the thumb in Raynaud's phenomenon. Rheumatology (Oxford) 47, 219-221 (2008
36. Bunker, C. B., Terenghi, G., Springall, D. R., Polak, J. M. and Dowd, P. M. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 336, 1530-1533 (1990
37. Coffman, J. D. and Cohen, R. A. Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur. J. Clin. Invest. 18, 309-313 (1988
38. Flavahan, N. A., Cooke, J. P., Shepherd, J. T. and Vanhoutte, P. M. Human postjunctional alpha 1 and alpha 2 adrenoceptors: Differential distribution in arteries of the limbs. J. Pharmacol. Exp. Ther. 241, 361-365 (1987
39. Chotani, M. A., Flavahan, S., Mitra, S., Daunt, D. and Flavahan, N. A. Silent a(2c)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am. J. Physiol. Heart. Circ. Physiol. 278, H1075-H1083 (2000
40. Flavahan, N. A. et al. Increased a2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 43, 1886-1890 (2000
41. Jeyaraj, S. C. et al. Cooling evokes redistribution of a2c-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol. Pharmacol. 60, 1195-1200 (2001
42. Bailey, S. R., Eid, A. H., Mitra, S., Flavahan, S. and Flavahan, N. A. Rho kinase mediates cold-induced constriction of cutaneous arteries: Role of a2C-adrenoceptor translocation. Circ. Res. 94, 1367-1374 (2004
43. Bailey, S. R., Mitra, S., Flavahan, S. and Flavahan, N. A. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol. 289, H243-H250 (2005
44. Flavahan, N. A. Regulation of vascular reactivity in scleroderma: New insights into Raynaud's phenomenon. Rheum. Dis. Clin. North Am. 34, 81-87 (2008
45. Yamazaki, F. Local ascorbate administration inhibits the adrenergic vasoconstrictor response to local cooling in the human skin. J. Appl. Physiol. 108, 328-333 (2010
46. Furspan, P. B., Chatterjee, S. and Freedman, R. R. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum. 50, 1578-1585 (2004
47. Furspan, P. B., Chatterjee, S., Mayes, M. D. and Freedman, R. R. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. Rheumatology (Oxford) 44, 488-494 (2005
48. Stephens, D. P., Saad, A. R., Bennett, L. A., Kosiba, W. A. and Johnson, J. M. Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans. Am. J. Physiol. Heart Circ. Physiol. 287, H1404-H1409 (2004
49. Ames, P. R. et al. The coagulation/fibrinolytic balance in systemic sclerosis: Evidence for a haematological stress syndrome. Br. J. Rheumatol. 36, 1045-1050 (1997
50. Fatini, C. et al. Hemorheologic profile in systemic sclerosis: Role of NOS3 786T>C and 894G>T polymorphisms in modulating both the hemorheologic parameters and the susceptibility to the disease. Arthritis Rheum. 54, 2263-2270 (2006
51. Postlethwaite, A. E. and Chiang, T. M. Platelet contributions to the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol. 19, 574-579 (2007
52. Pamuk, G. E. et al. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: A comparative study. Blood Coagul. Fibrinolysis 18, 297-302 (2007
53. Kallenberg, C. G., Vallenga, E., Wouda, A. A. and The, T. H. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J. Rheumatol. 9, 878-884 (1982
54. Lau, C. S. et al. Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. Br. J. Rheumatol. 31, 375-380 (1992
55. Solanilla, A. et al. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) 48, 1036-1044 (2009
56. Dees, C. et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J. Exp. Med. 208, 961-972 (2011
57. Gabrielli, A. et al. Oxidative stress and the pathogenesis of scleroderma: The Murrell's hypothesis revisited. Semin. Immunopathol. 30, 329-337 (2008
58. Freedman, R. R. and Mayes, M. D. Familial aggregation of primary Raynaud's disease. Arthritis Rheum. 39, 1189-1191 (1996
59. Susol, E. et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum. 43, 1641-1646 (2000
60. Frech, T. et al. Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: A population-based study. Arthritis Rheum. 62, 2109-2116 (2010
61. Eid, A. H. et al. Estrogen increases smooth muscle expression of a2C-adrenoceptors and cold-induced constriction of cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol. 293, H1955-H1961 (2007
62. Koenig, M. et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 58, 3902-3912 (2008
63. Cutolo, M., Pizzorni, C. and Sulli, A. Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: Comment on the article by Hirschl. et al. Arthritis Rheum. 56, 2102-2103 (2007
64. LeRoy, E. C. and Medsger, T. A. Raynaud's phenomenon: A proposal for classification. Clin. Exp. Rheumatol. 10, 485-488 (1992
65. Chikura, B., Moore, T., Manning, J., Vail, A. and Herrick, A. L. Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease. J. Rheumatol. 37, 783-786 (2010
66. Wigley, F. M. Raynaud's phenomenon. N. Engl. J. Med. 347, 1001-1008 (2002
67. Anderson, M. E., Moore, T. L., Lunt, M. and Herrick, A. L. The 'distal-dorsal difference': A thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon. Rheumatology (Oxford) 6, 533-538 (2007
68. Darton, K. and Black, C. M. Pyroelectric vidicon thermography and cold challenge quantify the severity of Raynaud's phenomenon. Br. J. Rheumatol. 30, 190-195 (1991
69. O'Reilly, D., Taylor, L., el-Hadidy. K. and Jayson, M. I. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis. Ann. Rheum. Dis. 51, 1193-1196 (1992
70. Maricq, H. R. and LeRoy, E. C. Patterns of finger capillary abnormalities in connective tissue disease by 'wide-field' microscopy. Arthritis Rheum. 16, 619-628 (1973
71. Herrick, A. L. and Cutolo, M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. 62, 2595-2604 (2010
72. Baron, M. et al. Office capillaroscopy in systemic sclerosis. Clin. Rheumatol. 26, 1268-1274 (2007
73. Cutolo, M., Sulli, A. and Smith, V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat. Rev. Rheumatol. 6, 578-587 (2010
74. Smith, V. et al. Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: A two-centre study. Ann. Rheum. Dis. 69, 1092-1096 (2010
75. Ingegnoli, F. et al. Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: Role of autoantibodies and nail-fold capillaroscopy. Rheumatology (Oxford) 49, 797-805 (2010
76. Sebastiani, M. et al. Capillaroscopic skin ulcer risk index: A new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum. 61, 688-694 (2009
77. Smith, V. et al. Nailfold capillaroscopy for day to day clinical use: Construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann. Rheum. Dis. 70, 180-183 (2011
78. Matucci-Cerinic, M. et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research Group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann. Rheum. Dis. 68, 1377-1380 (2009
79. Avouac, J. et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: Results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann. Rheum. Dis. 70, 476-481 (2011
80. Murray, A., Herrick, A. L. and King, T. A. Laser Doppler imaging: A developing technique for application in the rheumatic diseases. Rheumatology (Oxford) 43, 1210-1218 (2004
81. Herrick, A. L. and Clark, S. Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis. Ann. Rheum. Dis. 57, 70-78 (1998
82. Murray, A. K. et al. Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum. 61, 1103-1111 (2009
83. Korn, J. H. et al. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 50, 3985-3993 (2004
84. Chung, L. et al. MQX 503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon. Arthritis Rheum. 60, 870-877 (2009
85. Matucci-Cerinic, M. et al. Bosentan treatment of digital ulcers related to systemic sclerosis: Results from the RAPIDS 2 randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 70, 32-38 (2011
86. Kowal-Bielecka, O. et al. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. 68, 620-628 (2009
87. Thompson, A. E. and Pope, J. E. Calcium channel blockers for primary Raynaud's phenomenon: A meta-analysis. Rheumatology (Oxford) 44, 145-150 (2005
88. Thompson, A. E., Shea, B., Welch, V., Fenlon, D. and Pope, J. E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 44, 1841-1847 (2001
89. Herrick, A. Raynaud's phenomenon (secondary). Clinical Evidence (Online) 2008, 1125 (2008
90. Dziadzio, M. et al. Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 42, 2646-2655 (1999
91. Gliddon, A. E. et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 56, 3837-3846 (2007
92. Harding, S. E. et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews Issue 2. Art. No.: CD000956. http://dx.doi.org/10.1002/14651858.CD000956.
93. Coleiro, B. et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40, 1038-1043 (2001
94. Wigley, F. M. et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann. Intern. Med. 120, 199-206 (1994
95. Pope, J. et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews Issue 2. Art. No.: CD000953 http://dx.doi.org/10.1002/14651858.CD000953.
96. Fries, R., Shariat, K., von Wilmowsky, H. and Bohm, M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 112, 2980-2985 (2005
97. Caglayan, E. et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch. Intern. Med. 166, 231-233 (2006
98. Schiopu, E. et al. Randomised placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J. Rheumatol. 36, 2264-2268 (2009
99. Shenoy, P. D. et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: A double-blind randomized cross-over trial. Rheumatology (Oxford) 49, 2420-2428 (2010
100. Herrick, A. L. et al. Modified-Release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 63, 775-782 (2011
101. Herrick, A. L. Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr. Opin. Rheumatol. 23, 555-561 (2011
102. Brueckner, C. S. et al. Effect of sildenafil on digital ulcers in systemic sclerosis: Analysis from a single centre pilot study. Ann. Rheum. Dis. 69, 1475-1478 (2010
103. Dhaun, N., Pollock, D. M., Goddard, J. and Webb, D. J. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol. Sci. 28, 573-579 (2007
104. Bose, N. et al. Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging [abstract]. Arthritis Rheum. 62 (Suppl.), S239-S240 (2010
105. Tomaino, M. M., Goitz, R. J. and Medsger, T. A. Surgery for ischemic pain and Raynaud's phenomenon in scleroderma: A description of treatment protocol and evaluation of results. Microsurgery. 21, 75-79 (2001
106. Hartzell, T. L., Makhni, E. C. and Sampson, C. Long-term results of periarterial sympathectomy. J. Hand Surg. Am. 34, 1454-1460 (2009
107. Kuwana, M. et al. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum. 54, 1946-1951 (2006
108. Furukawa, S. et al. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: A pilot study. Ann. Rheum. Dis. 65, 1118-1120 (2006
109. Louneva, N., Huaman, G., Fertala, J. and Jimenez, S. A. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 54, 1298-1308 (2006
110. Derk, C. T. and Jimenez, S. A. Statins and the vasculopathy of systemic sclerosis: Potential therapeutic agents? Autoimmun. Rev. 5, 25-32 (2006
111. Abou-Raya, A., Abou-Raya, S. and Helmii. M. Statins: Potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J. Rheumatol. 35, 1801-1808 (2008
112. Fishman, A. P. Pulmonary hypertension-beyond vasodilator therapy. N. Engl. J. Med. 338, 321-322 (1998
113. Chrysant, S. G. Vascular remodeling: The role of angiotensin-converting enzyme inhibitors. Am. Heart J. 135, S21-S30 (1998
114. Kirchengast, M. and Munter, K. Endothelin 1 and endothelin receptor antagonists in cardiovascular remodeling. Proc. Soc. Exp. Biol. Med. 221, 312-325 (1999
115. Shenoy, P. and Agarwal, V. Phosphodiesterase inhibitors in the management of autoimmune disease. Autoimmun. Rev. 9, 511-515 (2010
116. Kleckner, M. Jr, Allen, E. V. and Wakim, K. G. The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud's disease and Raynaud's phenomenon: Studies on blood flow and clinical manifestations. Circulation. 3, 681-689 (1951
117. Teh, L. S. et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br. J. Rheumatol. 34, 636-641 (1995
118. Wigley, F. M. et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 41, 670-677 (1998
119. Seibold, J. R. et al. Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: A randomized, double-blind, placebo-controlled, multicenter study (abstract). Arthritis Rheum. 63 (Suppl.), S968-S969 (2011
120. Van Beek, A. L, Lim, P. K, Gear, A. J. and Pritzler, M. R. Management of vasospastic disorders with botulinum toxin A. Plast. Reconstr. Surg. 119, 217-226 (2007
121. Neumeister, MW. et al. Botox therapy for ischemic digits. Plast. Reconstr. Surg. 124, 191-201 (2009
122. Wise, R. A. et al. Efficacy and tolerability of a selective a2C-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients. a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum. 50, 3994-4001 (2004
123. Fava, A. et al. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon. Arthritis Care Res. 64, 925-929 (2012